Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription 12.10.2026 1 AJR Am J Roentgenol 1 Am J Pathol 5 Ann Surg Oncol 1 BMC Cancer 4 Breast Cancer 3 Breast Cancer (Dove Med Press) 2 Breast Cancer Res Treat 1 Breast J 1 Cancer Lett 2 Cancer Res 1 Clin Breast Cancer 2 Clin Cancer Res 2 Clin Exp Metastasis 3 Histopathology 1 J Biol Chem 1 J Clin Oncol 6 J Natl Cancer Inst 1 J Nucl Med 1 Lancet Oncol 1 N Engl J Med 1 Nat Rev Clin Oncol 1 Oncogene 1 Oncology 4 PLoS One 1 Radiol Imaging Cancer

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. MINICHETTI P, Cereser L, Versienti E, Francioso F, et al
   BI-RADS v2025: Key Updates and Implications for Breast Imaging Practice.
   AJR Am J Roentgenol. 2026 Jun 3. doi: 10.2214/AJR.26.35051.
   PubMed         Abstract available
   
   

   
   Am J Pathol

2. LIU S, Li J, Lian Y, Lan J, et al
   Foundation Model-Based Computational Pathology Predicts Breast Cancer Biomarker Status from Intraoperative Frozen Sections.
   Am J Pathol. 2026 Oct 5:S0002-9440(26)00284-1. doi: 10.1016/j.ajpath.2026.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. FLESHNER K, Amersi F, Chung A, Mirocha J, et al
   Lack of Utility of Ki-67 in Axillary Surgical Planning and Prognostication after Neoadjuvant Chemotherapy for Node-Positive Breast Cancer.
   Ann Surg Oncol. 2026 Oct 3. doi: 10.1245/s10434-026-20397.
   PubMed         Abstract available
   
   
4. FLESHNER K, Boyle MK
   ASO Author Reflections: Predicting Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer.
   Ann Surg Oncol. 2026 Oct 6. doi: 10.1245/s10434-026-20485.
   PubMed        
   
   
5. FLESHNER K, Amersi F, Chung A, Mirocha J, et al
   ASO Visual Abstract: Lack of Utility of Ki-67 in Axillary Surgical Planning and Prognostication After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer.
   Ann Surg Oncol. 2026 Oct 6. doi: 10.1245/s10434-026-20501.
   PubMed        
   
   
6. LEONARD SJ, Hoskin TL, Choong GM, Goetz MP, et al
   Endocrine Therapy Omission in Estrogen Receptor-Low (1-10%) Early Stage Breast Cancer: An Updated Analysis of the NCDB Database.
   Ann Surg Oncol. 2026 Oct 9. doi: 10.1245/s10434-026-20714.
   PubMed         Abstract available
   
   
7. ELSAEDY EA, AlRammah T, Kawashima K, Ebos JML, et al
   High Expression of Aurora Kinase A (AURKA) is Associated with Aggressive Tumor Biology and Therapeutic Response in ER+/HER2- Breast Cancer.
   Ann Surg Oncol. 2026 Oct 9. doi: 10.1245/s10434-026-20599.
   PubMed         Abstract available
   
   

   
   BMC Cancer

8. PETLELE R, Chikwati RP, Ojoniyi OO, Akokuwebe ME, et al
   Impact of and recovery after Covid-19 on breast cancer diagnosis and care in Johannesburg, South Africa.
   BMC Cancer. 2026;26:1182.
   PubMed         Abstract available
   
   

   
   Breast Cancer

9. ZHANG X, Chen PH, Chang WC, Jhou HJ, et al
   Target trial emulation of first-line ribociclib versus palbociclib in hormone receptor-positive, HER2-negative metastatic breast cancer: a comparative effectiveness study.
   Breast Cancer. 2026 Oct 6. doi: 10.1007/s12282-026-01921.
   PubMed         Abstract available
   
   
10. BAHARDOUST M, Rezaei A, Hosseinali A, Ranjbarpazuki G, et al
    Preoperative CA15-3 as a predictor of axillary lymph node metastasis and prognosis in women with breast cancer: a GRADE-assessed systematic review and meta-analysis.
    Breast Cancer. 2026 Oct 5. doi: 10.1007/s12282-026-01924.
    PubMed         Abstract available
    
    
11. KAKIMOTO S, Yamamoto H, Koike J, Tsugawa K, et al
    Long-term outcomes of invasive lobular carcinoma compared with invasive ductal carcinoma in HR-positive/HER2-negative breast cancer: a focus on luminal subtypes.
    Breast Cancer. 2026 Oct 3. doi: 10.1007/s12282-026-01922.
    PubMed         Abstract available
    
    
12. JO A, Iwamoto T, Kawada K, Suzuki Y, et al
    Effects of exercise and educational programs on long-term quality of life, anxiety, and depression in breast cancer survivors: an exploratory secondary analysis of the Setouchi breast project-10 randomized controlled trial.
    Breast Cancer. 2026 Oct 3. doi: 10.1007/s12282-026-01920.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

13. PAIN R, Beauchamp E, Duckett S, Kostiuk MA, et al
    Pharmacological Myristoylation Inhibition by Zelenirstat Disrupts Growth Signalling, Energy Metabolism, and Migration in Triple-Negative Breast Cancer Cells.
    Breast Cancer (Dove Med Press). 2026;18:619042.
    PubMed         Abstract available
    
    
14. XU X, Zhang Y, Fang H, Xu X, et al
    Cytoplasmic Basigin Localization is Associated with EMT, Tumor Budding, and Adverse Prognosis in Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:631016.
    PubMed         Abstract available
    
    
15. OBEAGU EI
    D-Dimer Dynamics as a Prognostic and Monitoring Biomarker in Triple-Negative and Metastatic Breast Cancer: A Narrative Review.
    Breast Cancer (Dove Med Press). 2026;18:637558.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

16. SUTEJITSIRI L, Suami H, Nielsen PMF, Phillips ARJ, et al
    A dermal backflow atlas of lymphatic dysfunction in breast cancer-related lymphedema with machine learning-based stage prediction.
    Breast Cancer Res Treat. 2026;219:28.
    PubMed         Abstract available
    
    
17. HARRELL M, Kutuk T, Gokun Y, Upadhyay R, et al
    Brain-only metastatic breast cancer as a distinct clinical entity: evidence from national and institutional cohorts with implications for radiation therapy.
    Breast Cancer Res Treat. 2026;219:29.
    PubMed         Abstract available
    
    

    
    Breast J

18. LALLER A, Gupta L, Bharti D, Chaudhary K, et al
    Comparison of Modified Pectoral Nerve Block and Erector Spinae Plane Block for Postoperative Analgesia and Surgical Stress Response Following Modified Radical Mastectomy: A Prospective, Randomised, Blinded Study.
    Breast J. 2026;2026:e2712790.
    PubMed         Abstract available
    
    

    
    Cancer Lett

19. KUMAR D, Silvestri V, Edmondson EF, Khan I, et al
    Preclinical evaluation of trastuzumab deruxtecan in a new HER2+ leptomeningeal colonization model.
    Cancer Lett. 2026;660:218786.
    PubMed         Abstract available
    
    

    
    Cancer Res

20. SENENT Y, Manguso RT
    Epigenetic Priming Sensitizes Metastatic Breast Cancer to Checkpoint Blockade by Rewiring the Tumor-Immune Microenvironment.
    Cancer Res. 2026 Oct 6:OF1-OF2. doi: 10.1158/0008-5472.CAN-26-3968.
    PubMed         Abstract available
    
    
21. LYU C, Wang M, Wang H, Qi Y, et al
    Paired Single-Cell Profiling Reveals Glutathione-Dependent Immune Evasion in Breast Cancer Liver Metastasis.
    Cancer Res. 2026 Oct 8. doi: 10.1158/0008-5472.CAN-26-1201.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

22. MAVROPOULOS P, Konstantis G, Tsaousi G, Baka S, et al
    The Immunomodulatory Effect of Various Anesthetic Factors and Techniques on Patients Undergoing Breast Cancer Surgery: A Systematic Review and Meta-analyses of RCTs.
    Clin Breast Cancer. 2026 Sep 11:S1526-8209(26)00165.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

23. SANTOS B, Bu D, Virostek M, Johnson E, et al
    Endotrophin is a circulating fibroinflammatory biomarker associated with treatment response in human metastatic ER+ breast cancer.
    Clin Cancer Res. 2026 Oct 5. doi: 10.1158/1078-0432.CCR-25-3775.
    PubMed         Abstract available
    
    
24. ZHANG D, Staaf J, Bendahl PO, Dihge L, et al
    Multimodal Gene Expression Deep Learning for Predicting Sentinel Lymph Node Macro-metastasis in Early Breast Cancer: Development and Validation in the SCAN-B Cohort.
    Clin Cancer Res. 2026 Oct 8. doi: 10.1158/1078-0432.CCR-26-1134.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

25. PEGUSHIN DA, Oganesyan MV, Nikolenko VN
    Exosome-mediated organotropism in breast cancer metastasis: bridging the gap between molecular mechanisms and clinical application.
    Clin Exp Metastasis. 2026;43:50.
    PubMed         Abstract available
    
    
26. STASCZAK A, Stankiewicz A, Topa J, Piesik Z, et al
    Mitochondrial transcript abundance in breast cancer circulating tumour cells may reflect both blood-derived transcripts and biological heterogeneity.
    Clin Exp Metastasis. 2026;43:52.
    PubMed         Abstract available
    
    

    
    Histopathology

27. RAKHA EA, Quinn C, Tan PH, Callagy G, et al
    Breast core needle biopsy diagnosis and personalized treatment: navigating pitfalls and challenging lesions.
    Histopathology. 2026;89:758-778.
    PubMed         Abstract available
    
    
28. STODDARD G, Ali R, Saglam O
    Navigating diagnostic challenges in low-grade spindle cell lesions of the breast: a retrospective review.
    Histopathology. 2026;89:786-795.
    PubMed         Abstract available
    
    
29. APORNVIRAT S, Hadi EJ, Gudi M, Bae YK, et al
    Malignant adenomyoepithelioma of the breast: seven cases illustrating morphological diversity and diagnostic challenges.
    Histopathology. 2026;89:807-823.
    PubMed         Abstract available
    
    

    
    J Biol Chem

30. GKIKAS M, Dadiotis E, Zaka M, Aly N, et al
    Ion Channel Nano-Diagnostics for ER+ Breast Cancer.
    J Biol Chem. 2026 Oct 8:113623. doi: 10.1016/j.jbc.2026.113623.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

31. CHMURA SJ, Winter KA, Woodward WA, Borges VF, et al
    NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer.
    J Clin Oncol. 2026 Oct 7:JCO2600201. doi: 10.1200/JCO-26-00201.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

32. PURJA S, Kim E
    Adaptive design increased success but does not significantly accelerate confirmatory oncology trials.
    J Natl Cancer Inst. 2026;118:1888-1898.
    PubMed         Abstract available
    
    
33. HALL P, Hammarstrom M, Bergqvist J, Czene K, et al
    Endoxifen for mammographic density reduction-results from the KARISMA endoxifen trial.
    J Natl Cancer Inst. 2026;118:1899-1906.
    PubMed         Abstract available
    
    
34. ABDOU Y, Hoag J, Barlow WE, Albain KS, et al
    Recurrence Score gene group components and outcomes in the RxPONDER trial (SWOG S1007).
    J Natl Cancer Inst. 2026;118:1953-1962.
    PubMed         Abstract available
    
    
35. VALENZA C, Zheng Y, Leone JP, Trapani D, et al
    21-Gene recurrence score assay in pN2-3 Early-Stage breast cancer: a national cancer database study.
    J Natl Cancer Inst. 2026 Oct 6:djag374. doi: 10.1093.
    PubMed         Abstract available
    
    
36. RAGHAVENDRA AS, Kotecki N, Jennings K, Amato O, et al
    A validated clinical calculator of a brain metastasis risk (BrMR) prediction model in stage I-III breast cancer patients.
    J Natl Cancer Inst. 2026 Oct 8:djag377. doi: 10.1093.
    PubMed         Abstract available
    
    
37. MURPHY PK, Sellers ME, Cronin KA
    Stat Bite: Breast cancer subtype incidence rates in women under 50 from 2019 to 2023.
    J Natl Cancer Inst. 2026;118:1987.
    PubMed        
    
    

    
    J Nucl Med

38. GE S, Li J, Shi J, Jia T, et al
    (68)Ga-Labeled Dimeric Cyclic Peptide for Nectin-4-Targeted PET Imaging: From Preclinical Evaluation to First-in-Human Imaging in Breast Cancer.
    J Nucl Med. 2026 Oct 8:jnumed.126.273306. doi: 10.2967/jnumed.126.273306.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

39. WEIGEL S, Hense HW, Weyer-Elberich V, Czwoydzinski J, et al
    Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial.
    Lancet Oncol. 2026 Oct 9:S1470-2045(26)00341.
    PubMed         Abstract available
    
    

    
    N Engl J Med

40. HURVITZ SA
    Advances in Systemic Treatment of Breast Cancer.
    N Engl J Med. 2026;395:1409-1425.
    PubMed         Abstract available
    
    

    
    Nat Rev Clin Oncol

41. TARANTINO P, Valenza C, Segui E, Lin NU, et al
    Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum.
    Nat Rev Clin Oncol. 2026 Oct 8. doi: 10.1038/s41571-026-01211.
    PubMed         Abstract available
    
    

    
    Oncogene

42. SONG H, Zhao Z, Ma L, Zhao W, et al
    Correction: Novel exosomal circEGFR facilitates triple negative breast cancer autophagy via promoting TFEB nuclear trafficking and modulating miR-224-5p/ATG13/ULK1 feedback loop.
    Oncogene. 2026 Oct 8. doi: 10.1038/s41388-026-04010.
    PubMed        
    
    

    
    Oncology

43. SCAFURI L, Buonerba C, Marotta V, Amato AR, et al
    Stage-specific quality of life and tolerability of CDK4/6 inhibitors in HR-positive/HER2-negative breast cancer: a narrative review.
    Oncology. 2026 Oct 7:1. doi: 10.1159.
    PubMed         Abstract available
    
    

    
    PLoS One

44. WENG X, Tang Y, Wang C, Huang Z, et al
    Patient overlap, cohort-relative scaling, and biological context in cross-cohort evaluation of a mitochondrial proteostasis-associated score in triple-negative breast cancer.
    PLoS One. 2026;21:e0355652.
    PubMed         Abstract available
    
    
45. RAHIM N, Shakeel S, Nouman M, Asim S, et al
    Development and clinical validation of HPLC method for precise quantification of paclitaxel in plasma from breast cancer patients.
    PLoS One. 2026;21:e0358891.
    PubMed         Abstract available
    
    
46. LEE DH, Byun KD, Kim TH, Lee J, et al
    Predicting red breast syndrome after ADM-assisted breast reconstruction: An exploratory scoring model using routine hematologic markers.
    PLoS One. 2026;21:e0359415.
    PubMed         Abstract available
    
    
47. FAROOQ K, Gull S, Farooq Z, Amin MT, et al
    Integrative methylome and transcriptome analyses identify LHX3 as an epigenetically downregulated marker with tumor suppressive properties in breast cancer.
    PLoS One. 2026;21:e0357378.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

48. VAN DER VEER EL, Bluekens AMJ, Coolen AMP, Vreuls W, et al
    Management, Upgrade Rates, and Radiologic Surveillance of Screen-Detected High-Risk Breast Lesions.
    Radiol Imaging Cancer. 2026;8:e260010.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum